RedHill Biopharma annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
RedHill Biopharma Depreciation & Amortization Growth & History (RDHL)
RedHill Biopharma's depreciation and amortization was $409,000 for fiscal 2025.
View full RedHill Biopharma company overviewRedHill Biopharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $409,000 | −$179,000 | −30.44% |
| 2024 | 2024-12-31 | $588,000 | −$857,000 | −59.31% |
| 2023 | 2023-12-31 | $1.4M | −$691,000 | −32.35% |
| 2022 | 2022-12-31 | $2.1M | $222,000 | +11.60% |
| 2021 | 2021-12-31 | $1.9M | $204,000 | +11.93% |
| 2020 | 2020-12-31 | $1.7M | $713,000 | +71.51% |
| 2019 | 2019-12-31 | $997,000 | $656,000 | +192.38% |
| 2018 | 2018-12-31 | $341,000 | — | — |
RedHill Biopharma quarterly depreciation and amortization
Q2.21
Q2.22
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2022 | 2022-06-30 | $617,000 | $152,000 | +32.69% |
| Q2 2021 | 2021-06-30 | $465,000 | — | — |
RedHill Biopharma depreciation and amortization trends
Over the last five fiscal years, RedHill Biopharma's depreciation and amortization decreased from $1.7M to $409,000, a change of −$1.3M. The latest reported quarter, Q2 2022, shows $617,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗